

# **Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020**

<https://marketpublishers.com/r/EB176CF43362EN.html>

Date: September 2020

Pages: 342

Price: US\$ 2,000.00 (Single User License)

ID: EB176CF43362EN

## **Abstracts**

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 2, 7, 59, 25 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 4, 13 and 7 molecules, respectively.

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their

major and minor projects.

The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Ebolavirus Infections - Overview

Ebolavirus Infections - Therapeutics Development

Ebolavirus Infections - Therapeutics Assessment

Ebolavirus Infections - Companies Involved in Therapeutics Development

Ebolavirus Infections - Drug Profiles

Ebolavirus Infections - Dormant Projects

Ebolavirus Infections - Discontinued Products

Ebolavirus Infections - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Alkido Pharma Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AIM ImmunoTech Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Akshaya Bio Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AntoXa Corp, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arisan Therapeutics Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Atreca Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Avipero Ltd, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Bharat Biotech Ltd, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioComo Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioFactura Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products, H2 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Abivax SA

Alkido Pharma Inc

AIM ImmunoTech Inc

Akshaya Bio Inc

AnGes Inc

ANP Technologies Inc

AntoXa Corp

Arisan Therapeutics Inc

Atreca Inc

Avipero Ltd

Beijing Mabworks Biotech Co Ltd

Bharat Biotech Ltd

BioComo Inc

BioCryst Pharmaceuticals Inc

BioFactura Inc

Biotron Ltd

Celdara Medical LLC

Chicago Biosolutions Inc

Cocrystal Pharma Inc

Collaborations Pharmaceuticals Inc



Eisai Co Ltd  
Emergent BioSolutions Inc  
Emergex Vaccines Ltd  
Etubics Corp  
Fab'entech SA  
Fibreu Ltd  
Flow Pharma Inc  
Fox Chase Chemical Diversity Center Inc  
Galactica Biotech Ltd  
Gamaleya Federal Research Center of Epidemiology and Microbiology  
GeoVax Labs Inc  
Gilead Sciences Inc  
Global BioLife Inc Ltd  
Greffex Inc  
H&P Labs Inc  
Humabs BioMed SA  
IDBiologics Inc  
Immunomodulation Inc  
Inovio Pharmaceuticals Inc  
Integral Molecular Inc  
Integrated BioTherapeutics Inc  
IntelliStem Technologies Inc  
Johnson & Johnson  
Mapp Biopharmaceutical Inc  
Merck & Co Inc  
Microbiotix Inc  
Micropharm Ltd  
Novavax Inc  
Oita University Institute of Advanced Medicine Inc  
OncXerna Therapeutics Inc  
Orgenesis Inc  
Ostrich Pharma USA Inc  
OyaGen Inc  
Palisades Therapeutics  
PanThera Biopharma LLC  
Phelix Therapeutics LLC  
Phoenix Biotechnology Inc  
Profectus BioSciences Inc  
Public Health Vaccines LLC

Regeneron Pharmaceuticals Inc  
Riboscience LLC  
Ridgeback Biotherapeutics LP  
Rodos BioTarget GmbH  
SAB Biotherapeutics Inc  
Secarna Pharmaceuticals GmbH & Co. KG  
Selva Therapeutics Inc  
Soligenix Inc  
Tiba Biotech LLC  
Vaccibody AS  
Vaxeal Holding SA  
XBiotech Inc  
Xenothera SAS  
Yaso Therapeutics Inc  
Yisheng Biopharma Co Ltd  
Zalgen Labs LLC

## I would like to order

Product name: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/EB176CF43362EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EB176CF43362EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970